^
Association details:
| Biomarker: | PD-L1 overexpression + CCL5 overexpression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Peripheral cytokine as a pan-cancer predictor for immunotherapy with anti-PD-1/PD-L1 antibody
Published date:
05/13/2020
Excerpt:
In the discovery cohort of ESCC patients, multiplex Luminex profiling data revealed that soluble PD-L1 and C-C motif chemokine 5 (CCL5/RANTES) were significantly upregulated in patients with clinic benefit at baseline.
DOI:
10.1200/JCO.2020.38.15_suppl.e15044
